Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
MedCity News14d
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
The company attributed the revision to lower-than-expected sales of tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for ... “We own that, it’s our job to give good guidance ...
Healthline8d
How to Get a Zepbound Prescription In Person and Online
Share on Pinterest Prescription weight loss medications may be useful for people looking to lose weight or maintain their weight loss when combined ... name Mounjaro since May 2022. Zepbound ...
STAT15d
Eli Lilly’s stock falls after 2024 guidance misses forecasts
Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. This is ...
Morningstar14d
Eli Lilly: Weak Preliminary Sales for Mounjaro and Zepbound; Shares Remain Overvalued
Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in ... The bottom line: We're maintaining our $580 per share fair value estimate for wide-moat Eli ...
Yahoo1mon
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...
MarketWatch8d
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and ...
Yahoo14d
Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched ...
Yahoo Finance3d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...
Nasdaq3d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks » Beyond Mounjaro and Zepbound, I'd encourage investors to take a serious look at Lilly ...
The Motley Fool4d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...